HW
BIO icon

Hancock Whitney’s Bio-Rad Laboratories Class A BIO Stock Holding History

Hancock Whitney’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-407
Closed -$201K – 613
2022
Q2 		$201K Sell
407
-595
-59% -$310K 0.01% 615
2022
Q1 		$564K Sell
1,002
-12,290
-92% -$7.41M 0.02% 434
2021
Q4 		$10M Buy
13,292
+222
+2% +$166K 0.32% 72
2021
Q3 		$9.75M Buy
13,070
+171
+1% +$128K 0.34% 73
2021
Q2 		$8.31M Sell
12,899
-146
-1% -$88.9K 0.27% 85
2021
Q1 		$7.45M Sell
13,045
-2,845
-18% -$1.68M 0.25% 86
2020
Q4 		$9.26M Buy
15,890
+132
+0.8% +$75.2K 0.31% 77
2020
Q3 		$8.12M Buy
15,758
+12,598
+399% +$6.38M 0.3% 82
2020
Q2 		$1.43M Buy
3,160
+163
+5% +$71.9K 0.05% 301
2020
Q1 		$1.05M Buy
2,997
+247
+9% +$90.8K 0.04% 357
2019
Q4 		$1.02M Buy
+2,750
New +$970K 0.03% 436
2016
Q2 		– Sell
-6,300
Closed -$861K – 572
2016
Q1 		$861K Hold
6,300
– – 0.04% 340
2015
Q4 		$874K Buy
+6,300
New +$873K 0.04% 334

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Hancock Whitney's BIO Position: Q3 2022 in Review

Hancock Whitney sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2022, closing a stake of 407 shares — an estimated $201K sold.

Hancock Whitney first reported a position in BIO in Q4 2015 and held it in 13 quarters. The position peaked at $10M in Q4 2021. 484 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

  • Hancock Whitney reported no remaining Bio-Rad Laboratories Class A position as of Q3 2022 after selling out during the quarter.
  • Hancock Whitney sold 407 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $201K.
  • Hancock Whitney first reported a position in Bio-Rad Laboratories Class A in Q4 2015 and held it in 13 quarters.
  • Hancock Whitney's Bio-Rad Laboratories Class A position peaked at $10M in Q4 2021.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on Hancock Whitney's 13F filing for Q3 2022, filed 26 Oct 2022.